Sensitivity, specificity, positive (PPV) and negative (NPV) predictive value in percent (exact 95% confidence interval in brackets) for CSF and MRI parameters regarding conversion of clinically isolated syndrome to definite multiple sclerosis.

<p>MRZR  =  AI for measles, rubella, zoster, two or more AI ≥1.5, MRZS  =  MRZ score >10, OCB  =  oligoclonal bands in cerebrospinal fluid, MRI  =  two or more lesions in T2-weighted magnetic resonance imaging of the brain.</p

Demographic data, CSF and MRI findings in patients with clinically isolated syndrome (CIS).

<p>CIS all  =  all patients with CIS, CIS-CIS  =  patients with CIS that remained CIS over follow-up, CIS-RRMS  =  CIS patients with conversion to MS over follow-up, EDSS  =  Kurtzke Expanded Disability Status Scale, AI  =  antibody index, MRZR  =  AI for measles, rubella, zoster, two or more AI ≥1.5, MRZS  =  MRZ score >10, OCB  =  oligoclonal bands in cerebrospinal fluid, MRI  =  two or more lesions in T2-weighted magnetic resonance imaging of the brain. NS  =  not significant, S  =  statistical significance. * CIS-CIS vs. CIS-RRMS</p

Additional file 1: Table S1. of DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Adverse Events independent from relation to therapy. (DOCX 26.2 kb

Additional file 2: Figure S1. of DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Consort diagram. Figure S2. Flow chart for the assessment of the clinical benefit. (DOCX 82.8 kb

Additional file 2: Table S2. of A language-based sum score for the course and therapeutic intervention in primary progressive aphasia

Summary of volumetric results in MRI within 1 year (visit 1 and visit 2) for all PPA subtypes and healthy controls. (PDF 154 kb